Related Experiment Videos
MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma
1Cancer Research Unit, University of Newcastle upon Tyne Medical School, UK.
Abstract:
In this study we have compared the effects of different pro-opiomelanocortin (POMC) peptides on melanogenesis and metastasis and their relationship to MSH receptor expression in B16F1 melanoma cells. All peptides, apart from beta-endorphin, increased melanogenesis and the order of potency was Nle4DPhe7-alpha-MSH greater than alpha-MSH greater than ACTH[1-39] greater than des-acetyl alpha-MSH greater than ACTH[1-24]. A similar order of potency was found for metastasis, except for ACTH [1-24], which had a relatively greater effect on metastasis. These findings suggest that the effects on melanogenesis and metastasis are mediated via the same receptor. The results of ligand binding studies also indicated the presence of a single receptor with a KD value for Nle4DPhe7-alpha-MSH of 62 +/- 16pM. This was consistent with crosslinking studies using [125I] Nle4DPhe7-alpha-MSH which produced a single 50-55 kD band on analysis by SDS-PAGE. However, the relative binding affinities of the different peptides, measured by displacement of [125I]-Nle4DPhe7-alpha-MSH, did not closely correlate with the relative potencies in stimulating melanogenesis and metastasis. This suggests that receptor activation and the subsequent biological response is not determined solely by binding affinity.
Insights
Different pro-opiomelanocortin (POMC) peptides stimulate melanogenesis and metastasis in melanoma cells via a single receptor. However, binding affinity does not solely determine biological response.
Area of Science:
- * Molecular Endocrinology
- * Cancer Biology
Background:
- * Pro-opiomelanocortin (POMC) peptides play roles in various physiological processes.
- * Melanogenesis and metastasis are key features of melanoma.
Purpose of the Study:
- * To compare the effects of different POMC peptides on melanogenesis and metastasis in B16F1 melanoma cells.
- * To investigate the relationship between POMC peptide activity and melanocortin-stimulating hormone (MSH) receptor expression.
- * To determine if melanogenesis and metastasis are mediated by the same receptor.
Main Methods:
- * Treatment of B16F1 melanoma cells with various POMC peptides.
- * Assays for melanogenesis and metastasis.
- * Ligand binding studies using radiolabeled Nle4DPhe7-alpha-MSH.
- * Crosslinking studies and SDS-PAGE analysis.
- * Displacement assays to measure relative binding affinities.
Main Results:
- * Most POMC peptides, excluding beta-endorphin, enhanced melanogenesis and metastasis.
- * Nle4DPhe7-alpha-MSH demonstrated the highest potency for melanogenesis.
- * ACTH[1-24] showed a relatively greater effect on metastasis compared to its effect on melanogenesis.
- * Ligand binding and crosslinking studies indicated a single MSH receptor.
- * Relative binding affinities did not perfectly correlate with biological potencies.
Conclusions:
- * A single receptor likely mediates the effects of POMC peptides on both melanogenesis and metastasis.
- * Receptor activation and biological outcomes are complex and not solely dependent on binding affinity.
- * Findings provide insights into POMC peptide signaling in melanoma progression.